Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Urinary Bladder Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 24Vincristine 20Carboplatin 18Doxorubicin 15Etoposide 14Melphalan 12Radiotherapy 11Filgrastim 11Cisplatin 11Magnetic Resonance Spectroscopy 10Isotretinoin 10Specimen Handling 9Peripheral Blood Stem Cell Transplantation 9dinutuximab 8Biopsy 8X-Rays 7Topotecan 7Temozolomide 7aldesleukin 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Busulfan 6sargramostim 5Irinotecan 5Vindesine 4Neoadjuvant Therapy 4Ipilimumab 4Ifosfamide 4Dacarbazine 43-Iodobenzylguanidine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neuroblastoma × efineptakin alfa × Clear all
NCT00923351 2018-06-15

Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
44 enrolled 13 charts
CNSSarcoma

Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡